Replies to post #50673 on Ariad Pharmaceuticals Inc fka ARIA

[rumrunner528]

Mican, in reading the article, I found this curious:

"Roche has earned a reputation as a disciplined acquirer, prepared to walk away from potential deals rather than overpay."

"Chief Executive Severin Schwan abandoned a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012"

Current market cap of ILMN is over $23 billion. I have thought of a reputation to label Roche with, but it may get my post deleted. I will abandon my plans to acquire any shares of Roche.

Rum

[Jesspro]

This is the more reason why I am sticking with ARIAD. It has one drug in the market. Another one close to being approved and 8/10 other indications in phase 2/3, not counting other indications destined for trials. They have a great lab churning out BIC molecules. They have a big interest in Bellicum. And they have what people call 'GOD' molecule waiting in the wing. We have an activist investor named Denner sitting in the board. Forget about the buyout. It is never going to happen unless they want it to happen and right now they don't want it to happen. Our recourse is to stick with it hoping that their perseverance will pay off soon rather than later or that they finally decide to sell it. Either way is good for me...jmo.